Clinical Trial Update: Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial (TRANS-SWITCH) is evaluating switching virologically suppressed transgender women with HIV to a dolutegravir plus lamivudine dual-thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Epivir (Lamivudine)
• Tivicay (dolutegravir)

Snippet

Sponsor: UBATEC | Conditions: HIV, HIV-1 | Phase 4 | Status: RECRUITING